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Abstract
The effect of placebo observed in schizophrenia clinical trials represents a growing problem that interferes
with signal detection for treatments, increases costs of development, discourages investment in schizo-
phrenia research and delays the introduction of new treatments. This paper seeks to clarify key issues
related to this problem and identify potential solutions to them. Differences between placebo effect and
response are characterized. Recent insights into the central nervous system mechanisms of placebo effect
are described. This is followed by a description of protocol/study design and study conduct issues that
are contributing to a growing placebo effect in clinical trials. Potential solutions to these problems are
provided.
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Introduction
In recent years there has been a trend towards in-
creasing placebo effects in clinical trials whose data
have been submitted for new drug applications
(NDAs) (Kemp et al. 2008). This has been associated
with diminishing drug–placebo differences in clinical
trials, which, in turn, has interfered with signal detec-
tion for new therapies (Loebel et al. 2010). Conse-
quences of this increasing placebo effect are increased
costs for drug development, more inconclusive and
failed trials, delays in the development of new anti-
psychotics or even the abandonment of the search for
new therapies because the risks and costs are seen
as too great. There may also be a reduction in the
perceived value of newer therapies as poor signal
detection is sometimes inappropriately interpreted
as newer therapies being less potent relative to older
therapies or that treatments are losing their effects
over time (Lehrer, 2010). In addition, meta-analytic
work based on trials conducted over an extended time
frame may be biased or difficult to do well, as trials
taken from different periods may not be directly com-
parable without addressing the progressive changes in
placebo effect over time.
The following review offers a definition of termin-
ology to provide the reader with an understanding
of the distinction between placebo effect and placebo
response and to clarify the mechanisms involved in
placebo responses. A discussion of the value and limi-
tations of placebo in clinical trials is also provided.
This includes an explication of placebo-related effects
and problems that have been identified in clinical
trials involving patients with schizophrenia. Potential
solutions to these problems are then discussed.
Defining placebo effect, placebo response
and nocebo
‘Placebo effect’ and ‘placebo response’ are distinct
entities, with a number of reviews discussing these
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often synonymously used terms in great detail
(Benedetti, 2008a, b ; Benedetti et al. 2007; Enck et al.
2008; Price et al. 2008; Zubieta & Stohler, 2009).
Technically, ‘placebo effect’ is the response observed
in the placebo arm of a clinical trial, which is produced
by the totality of the placebo biological phenomenon
combined with other potential factors contributing to
symptom amelioration, such as natural history, re-
gression to the mean, biases, judgement errors, etc.
On the other hand, ‘placebo response’ designates the
biological phenomenon in isolation, as can best be
studied in specifically designed experimental proto-
cols. This leads to a paradox, whereby the field seeks
to enhance the beneficial effects of placebo response in
clinical practice, while looking to reduce placebo effect
in clinical trials.
From a neuroscientific perspective, to suggest
that placebo (Latin ‘I shall please’), as associated
with placebo response, is inert is not accurate. ‘ Inert ’
suggests that the substance or treatment is devoid of
specific effects for the condition being treated.
However, a placebo cannot be inert if it produces a
response. A placebo response does not reflect a direct
pharmacological effect, but rather the response of the
brain to the perception of treatment. It is the symbolic
meaning of the treatment, rather than the treatment
itself, that triggers the placebo response. The placebo
need not be a ‘treatment’ either. Its archetype is, of
course, the sugar pill, but more general factors work
equally well. For example, the stimulus eliciting
the effect may be ascribed to one or all aspects of
the context surrounding the therapeutic act and the
simulation of a therapeutic situation may replace the
sugar pill.
Mechanisms for placebo effect or response
Different explanatory mechanisms have been pro-
posed for placebo effects or responses. Classical con-
ditioning theory posits the placebo effects or responses
as a result of Pavlovian conditioning. In this process,
the repeated co-occurrence of an unconditioned re-
sponse to an unconditioned stimulus (e.g. salivation
after the sight of food) with a conditioned stimulus
(e.g. a bell ringing) induces a conditioned response
(i.e. salivation that is induced by bell ringing alone).
Likewise, aspects of the clinical setting (e.g. taste, col-
our, shape of a tablet, as well as white coats or the
peculiar hospital smell) can act as conditioned stimuli,
eliciting a therapeutic response in the absence of an
active principle, because they have been paired with it
in the past. In the same way, the conditioned response
can be a negative outcome, as in the case of nausea
elicited by the sight of the environment where
chemotherapy has been administered in the past.
Classical conditioning seems to work best where
unconscious processes are at play, as in placebo
responses involving endocrine or immune systems.
Expectation theory conceives the placebo effect or
response as the product of cognitive engagement, with
the patient consciously foreseeing a positive/negative
outcome, based on factors as diverse as verbal in-
structions, environmental clues, previous experience,
emotional arousal and/or the interaction with care
providers. This anticipation triggers internal changes
resulting in specific experiences (e.g. analgesia/
hyperalgesia). Desire, self-efficacy and self-reinforcing
feedback all interact with expectation, potentiating its
effects. Desire is the experiential dimension of wanting
something to happen or wanting to avoid something
happening (Price et al. 2008), while self-efficacy is the
belief that one is able to personally manage the disease
with one’s own internal resources. Self-reinforcing
feedback is a positive loop, whereby the subject at-
tends selectively to signs of improvement, taking them
as evidence that the placebo treatment has worked.
Neurochemical and pharmacological effects
The last decade has witnessed the beginning of
clarification of neurochemical and pharmacological
details of placebo analgesia. Many studies have shown
that the opiate antagonist naloxone is able to reduce
or completely block the placebo effect/response
(Amanzio & Benedetti, 1999 ; Eippert et al. 2009;
Levine et al. 1978). Notably, placebo responders have
levels of b-endorphin in the cerebrospinal fluid that
are more than double those of non-responders ;
opioids released by a placebo procedure displayed the
same side-effects as exogenous opiates ; naloxone-
sensitive cardiac effects could be observed during
placebo-induced expectation of analgesia. Indirect
support also comes from the possible placebo-
potentiating role of the cholecystokinin (CCK) antag-
onist proglumide (Benedetti et al. 2007). Research
suggests that the CCK system counteracts the effects
of opioids, suggesting that the placebo effect may be
under the opposing influences of facilitating opioids
and inhibiting CCK. In some situations, a placebo ef-
fect/response can still occur despite blockade of the
opioid mechanisms by naloxone. This suggests that
systems other than opioids are implicated in the
regulation of placebo effect/response. Little is cur-
rently known on these non-opioid systems and further
research is needed to elucidate them. A detailed re-
view may be found in Benedetti (2008b).
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The advent of neuroimaging techniques and their
use for experimental purposes has added anatomical
and temporal details to the neurochemical information
regarding placebo effect/response. A study using
positron emission tomography (PET) suggests that
placebo effect/response in Parkinson’s disease is
mediated by dopamine (de la Fuente-Ferna´ndez et al.
2001). Placebo-induced changes in patients with
Parkinson’s disease were subsequently found to be
associated with the reduction of bursting activity
in subthalamic nucleus neurons (Fig. 1) (Benedetti
et al. 2004, 2009). Subsequently, Petrovic et al. (2002)
showed overlap in the brain activation pattern gener-
ated by opioid-induced analgesia and by placebo-
induced analgesia. Both approaches activated areas
in the rostral anterior cingulate cortex and the orbito-
frontal cortex. Subsequently, in spite of some dis-
crepancies likely explained by methodological and
procedural differences, PET, functional magnetic res-
onance imaging and magnetoelectroencephalography
studies have suggested that placebo effect/response is
mediated through activation of the descending pain
control system, with modulation of activity in areas
such as periaqueductal grey, the ventromedial med-
ulla, the parabrachial nuclei, the anterior cingulate
cortex, the orbitofrontal cortex, the hypothalamus and
the central nucleus of the amygdala (Zubieta &
Stohler, 2009).
Utility and feasibility of conducting placebo
studies in schizophrenia
Discussion around placebo-controlled clinical trials in
schizophrenia patients has mainly focused on ethical
issues. The World Medical Association’s Declaration
of Helsinki (World Medical Association, 2008) is often
cited in this context. This declaration stipulates that :
The use of placebo is acceptable in studies where no
current proven intervention exists ; or where for com-
pelling and scientifically sound methodological rea-
sons the use of placebo is necessary to determine
efficacy or safety of an intervention and the patients
who receive placebo or no treatment will not be sub-
ject to any risk of serious or irreversible harm. Extreme
care must be taken to avoid abuse of this option.
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Fig. 1. Differences in neural activity in placebo responders and placebo non-responders. These panels depict the relationship
between clinical placebo response, as assessed through muscle rigidity at the wrist (a) and electrophysiological placebo
responses, as measured by means of a single neuron recording (b), in Parkinson’s disease. Note that in placebo responders (left),
both muscle rigidity decreases and electrophysiological changes occur, whereas in placebo non-responders neither clinical nor
electrophysiological changes take place (Benedetti et al. 2004, 2009).
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Many investigators and, very importantly, regulatory
agencies such as the Food and Drug Administration
in the US and the European Medicines Agency
have taken the position that a true appreciation of
an intervention against schizophrenia, as well as the
evaluation of such an intervention’s safety, is not
possible outside the methodology of a placebo-
controlled design, with the sole exception that the
experimental intervention shows superiority over ex-
isting treatments. This perspective has had a tremen-
dous impact on drug development. Consequently,
every antipsychotic that has been approved for
the treatment of schizophrenia in either the US or
Europe in the past 20 yr has been assessed in placebo-
controlled clinical trials. This practice has been
challenged by the increasing reluctance of clinician
researchers (Fleischhacker & Burns, 2002) and patients
(Hummer et al. 2003; Roberts, 1998) to participate in
such studies. Ethical committees in many countries
of the world are setting stricter standards, making it
increasingly difficult to conduct placebo-controlled
central nervous system (CNS) clinical trials. Where
such studies are allowed, care must be taken to mini-
mize any risks to subjects participating in these
trials. Consequently, feasibility problems complicate
the conduct of this research. All of these concerns
are augmented by studies that have found large drop-
out rates in clinical trials utilizing placebo controls
(Kemmler et al. 2005) as well as a decrease of the
placebo/drug difference (Kemp et al. 2008; Loebel et al.
2010) in clinical trials comparing both experimental
molecules and approved antipsychotics with well-
established efficacy to placebo.
Placebo effects in clinical schizophrenia
treatment trials
Placebo effects, more broadly defined as any con-
tributor to apparent symptom amelioration in clinical
trials, appear to be increasing for the acute treatment
studies in schizophrenia (Fig. 2) (Kemp et al. 2008).
Supportive evidence for this was observed in a com-
parison of placebo effect observed in studies from two
different phase III clinical development programmes
that were used to support registration of two anti-
psychotic medications. These programmes were com-
pleted about 10 yr apart and had similar designs ;
therefore, giving us an opportunity to examine pla-
cebo effect over time and across different regions of
the world. Placebo effect was determined based on
the placebo group’s least square mean change of the
Positive and Negative Syndrome Scale (PANSS) total
scores obtained from the analysis of covariance model
with factors of treatment and region (when the trial
was multi-regional) and the covariate of baseline
PANSS total scores. As illustrated in Fig. 3, in these
trials, placebo effects measured by amount of re-
duction in the PANSS total score increased over time
(Kemp et al. 2008).
Examination of potential drivers of placebo effects,
including age, race, gender and baseline symptoma-
tology, showed significant associations only for gen-
der and age (Fig. 4a, b). However, the more recent
trials had an approximate 1.6-fold greater risk for
placebo effects. Detailed evaluation of all participants
in acute trials compared to those who completed these
trials suggests that the differences in placebo effect
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Fig. 2. Placebo effect in acute schizophrenia trials over time. The mean change from baseline in total Positive and Negative
Syndrome Scale (PANSS) scores for subjects receiving placebo across randomized, double-blind, placebo-controlled, clinical
trials has increased in the direction of greater improvements that is correlated to the year that the studies were conducted.
(Adapted from Kemp et al. 2008.)
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may be driven by those subjects who completed the
study and not by those who dropped out early. It was
also observed that this placebo effect was most obvi-
ous in subjects originating from the USA. In this study,
placebo effect was also present in other regions of the
world and appeared to grow there over time.
In a recent publication, Chen et al. (2010) identified
10 schizophrenia drug programmes in support of
NDAs that were submitted to the US Food and
Drug Administration between December 1993 and
December 2005. The investigators considered study
data from all randomized, multi-region, multi-centre,
double-blind, placebo-controlled trials. Through this,
they identified 31 trials [22 positive and nine negative
(i.e. none of the study drug groups showed significant
results)] that included 12 585 patients from 37 coun-
tries (64% North America). In the US trials, placebo
effects as measured by reduction in the PANSS total
score increased over time, with no apparent trend over
time observed in the non-US or ‘mixed’ trials. Placebo
effect was associated with an estimated increase of
0.97 points in the reduction of the PANSS total score
per year during the 12-yr span (nominal p=0.0015;
Chen et al. 2010). These results (Chen et al. 2010) con-
firm the earlier finding (Kemp et al. 2008) that placebo
effect has increased over time in schizophrenia trials
and has been greater in trials performed in the US.
Factors potentially impacting upon placebo effect
in clinical trials
Several potential protocol/study design and conduct-
related factors may account for the placebo effect ob-
served in schizophrenia trials. In a recently presented
analysis of signal detection, Loebel et al. (2010)
similarly noted that protocol/study design factors,
patient’s prior research involvement and duration of
illness, recruitment methods and study site charac-
teristics affect the likelihood of detecting treatment
efficacy signals in schizophrenia trials. These potential
contributors to placebo effect are summarized in
Table 1 and discussed in more detail in the following
sections.
Protocol/Study design factors
Good protocol design is a critical component for miti-
gating placebo effect. Ironically, the desirability of
placebo controls has become even more apparent as
the placebo effect has become greater, more inconsist-
ent and less predictable. These inconsistencies and
the unpredictability of both placebo and drug effects
over time have fuelled resistance to the use of non-
inferiority trials against marketed agents as a substi-
tute for placebo-controlled trials for assessing both
the efficacy and safety of novel compounds. Although
non-inferiority trials are reasonable and feasible
alternatives for addressing important clinical ques-
tions (Fleischhacker et al. 2003), their design and con-
duct include features that are quite different from
superiority trials, which must be clearly addressed
during conception and interpretation.
Frequent, numerous or difficult assessments may
impact placebo effects by exhausting the patient, such
that they fail to complete assessments or provide in-
valid responses, leading to problems of both missing
data and increased measurement variance. Poor choi-
ces in the selection of assessment instruments may
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Fig. 3. Changes from baseline in total Positive and Negative Syndrome Scale (PANSS) scores in placebo-treated patients
(baseline to endpoint) from two phase III antipsychotic development programmes. Analysis of the changes from baseline in
total PANSS scores in placebo-treated patients enrolled in two phase III antipsychotic development trials, with earlier trials
conducted nearly a decade prior to the later trials, revealed an increased effect of placebo over time.
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also enhance placebo effect. Choice of a subjective,
rather than an objective, endpoint may permit the in-
troduction of increased inter- and intra-individual
response variance as well as greater rater and/or
patient bias. Similarly, the wording of questions used
to gather information may result in biased responses.
Poorly designed scales may not sensitively identify
critical symptom differences or may be associated with
high levels of rating variance/noise, which diminishes
their effectiveness for discriminating among various
treatments. The number of doses or treatment arms
may enhance the placebo effect by increasing the per-
ception of the likelihood for clinical success. Study
duration may also have a role in the magnitude of a
placebo effect. For instance, event-driven endpoints
are likely to converge over long periods of time if
the event is highly likely or inevitable over a long
period (e.g. death or relapse in a chronic condition).
On the other hand, for conditions such as schizo-
phrenia, short studies may be more responsive to
rater bias, Hawthorne effects and/or placebo response
than longer studies, which allow the disease to fully
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Fig. 4. Potential drivers of placebo effect in schizophrenia trials. Based upon multiple regression models and selection criteria
of pf0.2, there were few variables associated with placebo effect in either the week 6 completer population (a) or the last
observation carried forward (LOCF) analysis (b). With the exceptions of gender and age in the week 6 completer analysis, no
other variables were associated with a placebo effect. There was, however, in more recent conducted trials a nearly 1.6-fold
greater risk for placebo effect in both analyses.
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manifest itself. If concomitant medications are per-
mitted, they too may have small but measurable ef-
fects on clinical endpoints that obscure differences
between treatment arms.
Clinical trials are often initiated with persons who
are acutely ill. In such patients, the natural course of
the disease, the initial acuity, the hospital milieu and
the added attention provided by a research trial could
lead to regression to the mean at subsequent evalu-
ations and enhance an apparent placebo effect. Loebel
et al. (2010) noted that a larger active treatment–
placebo effect size was observed where subjects were
more likely to be research naive and had longer
illness durations. A number of the factors outlined
above may compromise study completion by patients.
Ensuing high drop-out rates jeopardize meaningful
statistical analyses and generalizability of data
(Kemmler et al. 2005).
Study conduct factors
The relationship of the subject to the study physician
and increased attention from the research staff may
result in improvement for all subjects in the trial.
Incentives for patients and/or raters that may lead to
culture-specific or compensation-specific increases in
placebo effects include subjects enrolled from back-
grounds where the clinician is particularly esteemed
and subjects have a culturally driven incentive to
please him or her as well as the availability of monet-
ary rewards for participation. The conduct of trials in
countries where patients have limited access to health-
care is likely to influence recruitment and, potentially,
study outcomes. For treatments where clinical benefit
is supported by prior results, both subjects and in-
vestigators/raters may be prone to look for and mag-
nify clinical improvement after randomization into
clinical trials, leading to expectation bias. There may
also be instances in which it is either very desirable to
demonstrate substantial improvement (e.g. as a con-
sequence of the erroneous assumption that a sponsor
is pleased by positive results) or no improvement
(e.g. if patients fear to lose pensions or benefits if they
get better).
Clinical trial recruitment strategies vary enor-
mously from site to site andmay be driven by financial
factors or sponsors that emphasize rapid recruitment/
enrolment methods – with these having an impact on
placebo effects. The appropriateness of the recruit-
ment/enrolment methods may vary depending
upon the nature of the target population (e.g. acute
exacerbation, persistent residual symptoms, refractory
symptoms, etc.). Some recruiting agencies or sites pay
fees to patients for their participation in the trial.
While these fees are usually regulated by an In-
vestigational Review Board at the site, there is con-
siderable variation in what is considered appropriate
or acceptable. Advertising to enrol patients has led
to the phenomenon of ‘professional’ patients who
will enrol in multiple trials sequentially, or even con-
currently. These patients might exaggerate their
symptoms in order to be eligible for a trial, which has a
considerable impact on treatment outcomes.
Other study conduct issues may mask or obscure
differences between treatments. For instance, if clinical
raters are inadequately trained, theymay not be able to
discriminate clinically important differences between
treatments. Many sponsors monitor sites to ensure the
Table 1. Placebo effect in clinical trials of schizophrenia : potential factors and specifics
Factors Specifics
Protocol/study design Includes a variety of study design factors such as : inclusion/exclusion criteria, number of
treatment arms, trial duration, presence of a lead-in phase, outcome measures, ‘response’
criteria and other factors
Also includes patient characteristics, such as age, gender, prior treatments, medical history, etc.,
and assessment strategies, such as the selection of rating scales, rater training, inter-rater
reliability, blinding and biases
Study conduct factors Includes study site selection (i.e. hospital, clinic or clinical trial centre), recruitment strategies
(i.e. advertising, patient payments) and the use of site payments or incentives. Quality
control factors including rater issues such as training and reliability, blinding and biases
can also be included
Regional/international
variability
Includes variations in healthcare standards and practices as well as demographic differences
that occur across multi-centre trials and particularly across multi-national trials. Factors include
patients’ access to medications, cultural/ethnic differences in symptom presentation and
their willingness to participate in research
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adequacy of study conduct ; if this is not done with
sufficient rigor, variance may be increased and the
sensitivity of the study may be diminished. For some
treatments, inadvertent unblinding of the treatment
assignment may bias results. For example, side-effects
or the taste of one test compound in a trial may be
sufficiently different from other comparators to permit
subjects to become aware of treatment assignment.
Encapsulated medications present the possibility for
unblinding by the inquisitive subject who opens the
capsule. Finally, fraud, although infrequent, is a con-
sideration for which study sponsors must be vigilant.
Regional/International variability factors
In studies conducted across various regions or coun-
tries healthcare access and utilization can vary wide-
ly. In addition to the patient’s access to clinicians
and medications, which may strongly impact patients’
willingness to participate in clinical trials, cultural and
ethnic differences may result in differences in symp-
tom presentation, description and ratings of severity.
Taken together all of these factors may contribute to
increased variability within each treatment arm and
so make it more difficult to differentiate treatment re-
sponses between arms. Further, these local population
differences may result in patient selection biases. On
the other hand, broadly based clinical trials increase
the generalizability of findings for that study.
Potential solutions or remedies for placebo effects
Given the importance of finding safe and more effec-
tive treatments in efficiently designed CNS clinical
trials, it is important to identify remedies that can be
brought to bear on the problem of inconsistent, un-
predictable and, at times, inordinately large placebo
effects. Solutions to the problem of placebo effects in
clinical trials depend heavily upon acknowledgement
of the problem, followed by its accurate assessment
and analysis.
Protocol/Study design
Suggestions to improve clinical trial design include
selecting an optimal number of assessment scales
with good psychometric properties and clear anchors.
Frequency of scale administration should be limited so
as to reduce both subject and rater fatigue. Study
duration should provide optimal time to address the
study question. Encouraging mutually shared ac-
countability among persons who design the trials,
persons who oversee the implementation and day-to-
day conduct of clinical trials, e.g. contract research
organizations, and investigators may improve both
design and outcomes. Care should be taken to avoid
unnatural trial environments that excessively mini-
mize stress that will be seen in ‘real-world’ environ-
ments.
The value of lead-in phases to ascertain stability or
non-response for eligibility to enter a prospective trial
is complicated when investigators know what will
determine eligibility. Investigators may be vulnerable
to adjust ratings in order for patients to meet eligibility
criteria, a phenomenon termed ‘baseline inflation’.
A placebo lead-in phase has an inconsistent impact on
reducing placebo effects and will vary depending
upon the nature of the trial (e.g. acute treatment, aug-
mentation, maintenance of effect, etc.). Some sponsors
have tried to blind the sites (i.e. raters) in terms of the
length of the placebo wash-out phase, the criteria for
patient inclusion in analyses and other factors. Clearly,
the ‘placebo’ effect also occurs among patients re-
ceiving active medications and, even in trials where
there is no placebo arm, there can be a surprising de-
gree of ‘placebo’ effect. Supporting this, a surprising
degree of placebo improvement may occur when
patients are switched to another agent or a second
treatment is added, even in trials where patients have
been selected on the basis of ‘stable persistent residual
symptoms’ (Kane et al. 2009).
Patients’ eligibility criteria in terms of demo-
graphics, medical/treatment history and potential
sites of recruitment are important elements in protocol
design and the phenomenon of placebo effect. In acute
schizophrenia trials, the intended patient is usually
someone who has had a clear exacerbation/relapse
with a marked, clinically significant worsening of
symptoms. Such patients are most often found in
acute care hospitals. However, patients frequently en-
rolled in clinical trials are those who have persistent
residual symptoms that are severe enough to meet
eligibility criteria, but have not had an acute exacer-
bation and have experienced continued symptoms
despite adequate treatment. Such patients are ident-
ified in out-patient programmes, day/partial hospital
programmes, adult homes and residential facilities
or through advertising and are then admitted to
hospital or professional clinical trial centres in order
to participate in the clinical trial. It is not surprising
to see either a high rate of placebo effect or a low rate
of drug effect in such patients, although obviously
each of those possibilities will be determined by
different factors. Since it is generally left to the
investigator’s judgement as to whether there has been
an acute exacerbation, and it is often difficult to find
quantitative documentation of worsening symptoms
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retrospectively, this remains an important issue
for sponsors. Therefore, methods to ensure that the
desired target population is enrolled in the trial
are essential. This is not to say that a signal for efficacy
cannot be detected in a population of patients with
persistent residual symptoms; however, this re-
presents a distinct treatment-refractory population
and that should be clearly identified as a desired
characteristic of the study population. On the other
hand, if such a population is not desired for the study,
they should be excluded as their inclusion is likely to
add considerable ‘noise’ to the data.
To manage placebo effects related to ascertainment
bias, some have argued for designing trials with over-
inclusive criteria, but having an ‘a priori criteria’ that
define a specific subpopulation that will be utilized in
the primary analysis. It is likely that the data collected
on patients who were not technically ‘eligible’ can be
put to good use and this might reduce the risk of
various biases and misaligned incentives regarding
patient recruitment. Clearly, this would involve
greater resources from the sponsor and such an ap-
proach would only be appropriate to address ques-
tions where the additional resources use can be
justified.
The use of an early response/non-response para-
digm (Correll et al. 2003; Kinon et al. 2008, 2010) is
another study design worth considering in order to
enhance the selection of true drug responders, who
can then participate in a double-blind, placebo-
controlled discontinuation trial. This strategy involves
treating all patients with the experimental drug (with
or without an active control) and then identifying
those subjects who have at least a minimal (i.e. 20%)
improvement on a specified subset of items after 2 wk
treatment. This offers the advantage of potentially
eliminating a substantial proportion of the patients
who are less likely to respond to any type of treatment
or intervention. In recent retrospective and prospec-
tive studies employing this paradigm, approximately
70% of patients fall into the early ‘non-response’
group. Although these patients do go on to improve
more over the next weeks or months, they never
improve as much as the ‘early responders’. The as-
sumption would be that the early responders would
include a greater proportion of patients who are truly
drug responsive, although it would also include some
proportion of ‘placebo responders’. Because such
patients represent a group enriched for drug respon-
siveness, they are an ideal subgroup to enter into a
double-blind discontinuation study, where, following
stabilization, patients are randomized to continued
treatment or placebo and time to destabilization is
the endpoint. Use of such an enriched population into
these studies would likely increase the anticipated
effect size for the study and reduce the overall number
of individuals who are exposed to placebo.
Study conduct factors
Variability among sites with regard to patient recruit-
ment techniques, as well as study participation/
enrolment incentives, may drive a substantial portion
of the placebo effect. For instance, individuals who
have been hospitalized, but have already received
treatment for several weeks without adequate re-
sponse and are then referred or recruited for partici-
pation in a clinical trial can influence trial outcomes.
This would likely increase the risk of enrolling poor or
partially responsive (or even refractory) patients into
the trial. Putting limits on the duration of the current
‘episode’ (although as previously indicated this
would require careful documentation) or the duration
of the current hospitalization (easier to document, but
still does not confirm the presence of an acute exacer-
bation) or the duration of current treatment could help
to reduce this risk. The variability in clinical trial re-
cruitment strategies is a study conduct factor that may
affect placebo effects and requires review in order to
mitigate the impact. Recognition of the impact of these
recruitment/enrolment variables and incentives and
their minimization should be considered in order to
reduce their effect on trial outcomes.
Other study conduct factors to be considered
include clinical rater skill and training, validity and
reliability of ratings in clinical trials, as well as the skill
of monitors reviewing this work. True inter-rater re-
liability requires that different interviewers conduct
interviews with the same patient and arrive at scores
that (based on statistical tests) fall within a specified
a priori range of agreement. In reliability studies based
on the assessment of a videotape, or multiple raters
assessing the same live patient, error variance is
enormously reduced, because the questions are asked
once by the same person and everyone uses the same
interview to judge symptom severity. Such an ap-
proach assesses the rater’s ability to agree on the se-
verity and intensity of the reported symptoms. It does
not establish the rater’s ability to conduct a skilful in-
terview that is thorough and unbiased. The type of
rater training that is required to achieve true inter-
rater reliability is rarely done in clinical trials because
it is very time-consuming and expensive. Usually
would-be raters are asked to rate a few videotapes
(an insufficient number for meaningful statistical
testing to be applied) and some predetermined level
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of agreement with a ‘gold standard’ rating score on
each item is deemed sufficient to declare the rater eli-
gible. The degree to which there is rater turnover and
drift in rater performance is often not the focus of
sufficient attention. Good inter-rater reliability is im-
portant because it has an enormous impact on stat-
istical power and, therefore, sample size requirements.
As summarized in Table 2, the use of raters with a high
intraclass correlation coefficient [(ICC) ; a measure of
how similar raters are to each other within a cohort of
raters] is inversely related to the sample size needed
to feel confident in the study results statistical power
(i.e. higher ICC requires less participants per study
arm) (Kobak et al. 2009).
Study conduct should control for clinician as well
as patient biases. Patient enrolment incentives play an
important role when sites are paid on a per-patient
basis. Many eligibility criteria are subjective and
potentially influenced by bias. Examples include the
inflation of baseline scores in order to meet patient
eligibility requirements or deflation of scores if scores
above a certain level are exclusionary. This is not only
related to symptom severity but also to interpretation
of selection criteria regarding whether patients are
appropriate for inclusion in the trial. Expectation bias,
demonstrated in clinical trial assessments (Davidson
et al. 2009; Goldberg et al. 2007; Woods et al. 2005), may
come from a variety of sources, including clinicians,
patients, patient caregivers, etc. It has been shown
that expectancy bias can be reduced when raters are
well trained as well as when different raters with high
inter-rater reliability evaluate the patient over time as
compared to the same rater rating the patient at each
visit. In order to effectively use different raters across
time points to reduce bias, true inter-rater reliability
must be established. Functional unblinding and re-
sulting bias can also occur when certain side-effects
develop that are more likely to occur in one treatment
arm than another. This bias is reduced when different
raters evaluate the patient over time.
Several approaches can be used to mitigate study
conduct factors and enhance the quality and precision
of the study assessments. One is to conduct extensive
rater training, followed by careful follow-up super-
vision. Quality control measures can be instituted,
such as videotaping or audiotaping some or all of the
assessment sessions for review by an external expert,
who can then provide feedback and further training to
the rater if problems are identified. Other potential
solutions include having an external expert randomly
participate in the interview via telephone or two-way
video or having the assessments conducted in their
entirety by remote, centralized assessors using tele-
phone or live two-way video. Other approaches in-
clude incentive payments for sites that are based on
the quality of assessments rather than on merely the
number of patients entered into the trial and keeping
and publishing a registry of trial performance. The
latter approach is similar to quality requirements that
hospitals are increasingly required to meet regarding
their outcome data. Such an approach would require
that criteria for study conduct quality be established.
Drug placebo differences would not be a reliable
measure of quality as trials may include active con-
trols that may have small or no clinical effects. Further,
there is usually large variability in the study popu-
lation, such that chance alone may lead to lower effect
sizes at particular sites and, given the relatively small
contribution of any site to the overall sample in large
multi-centre studies, it is difficult to differentiate a re-
sponse effect size that is below the mean from normal
variation.
Regional/International variability
It is important to recognize regional differences in
trial implementation and patient recruitment as drug
development programmes are increasingly global. In
some countries or regions, the opportunity to partici-
pate in a clinical trial might provide access to a more
comprehensive standardized evaluation, as well as
access to subsidized care and medication.
Cross-cultural differences in sites of multi-centre
studies lead to the potential misinterpretation of
the study selection criteria and goals. The spirit of the
protocol may not be fully understood or adhered to,
leading to technical adherence to the study design
but loss of the spirit of the protocol. Personnel con-
ducting the study may not have sufficient skills or
time to ensure that the spirit of the protocol was al-
ways maintained. Different incentives or inadequate
Table 2. Effect of interviewer reliability on study power
Reliability : intraclass
correlation coefficient
score
Sample
size
per arm
1.00 100
0.90 111
0.80 125
0.70 143
0.60 167
0.50 200
Adapted from Kobak et al. (2009).
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understanding may impact upon patient selection,
patient ratings and trial outcomes.
In an attempt to mitigate regional and inter-
national variability factors, researchers may consider
stratification of the trial findings by regions. Examin-
ation of salient differences by regions may also be
beneficial.
Summary
The design and conduct of clinical trials presents a
complex array of challenging problems, one of which
is that of the placebo effect. The first step in addressing
the issue of placebo effect is acknowledgement of its
existence. We must then focus on its potential causes
in order to adjust clinical trial design elements.
Clearly, the sources of placebo response are diverse.
Understanding placebo response as a neurobiological
effect is different from the sources of ‘placebo re-
sponse’ in a population that includes a much broader
range of issues that relate to trial design, conduct
and factors such as ascertainment bias and regression
to the mean. The latter may be associated with strong
regional differences. All of these factors should be ta-
ken into consideration when interpreting results from
clinical trials.
Increasing placebo response is frequently associ-
ated with increased variance around study endpoint
measurement, leading to poor signal detection. This,
in turn, has led to increasing sample sizes, increasing
numbers of failed studies and much higher treatment
development costs. Therefore, failure to address these
issues threatens the support for investments in and the
success of CNS drug development.
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